drugset

drugset / Trial / NCT01813630

A Clinical Study to Assess the Efficacy and Safety of DA-3002

NCT01813630 ↗

Phase 3 Completed 58 enrolled Dong-A ST Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

A study demonstrates the non-inferiority of DA-3002 when compared with Genotropin®.

Timeline

Start: 2013-02
Primary completion: 2018-05
Completion: 2018-05

Publications

Kim J, Kim MS, Suh BK, Ko CW, Lee KH, Yoo HW, Shin CH, Hwang JS, Kim HS, Chung WY, Kim CJ, Han HS, Jin DK. Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial. BMC Endocr Disord. 2021 Dec 10;21(1):243. doi: 10.1186/s12902-021-00904-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DA-3002	Protein / enzyme biologic	0.14 iu/kg	Other
Comparator	Somatropin	Protein / enzyme biologic	0.14 iu/kg	Other

Indications